A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
This is a registrational, first-in-human, open-label, dose escalation and expansion study evaluating the safety, tolerability and effectiveness of TTX-381, administered by injection under the retina, for the treatment of eye problems caused by CLN2 (Batten disease). The study includes dose escalation and expansion groups evaluating treatment in one or both eyes. Participants are followed for 5 years after treatment to assess safety and clinical outcomes.
∙ Participants must meet all of the following criteria:
• Biallelic CLN2 mutations.
• Decreased leukocyte TPP1 activity.
• Clinical signs or symptoms consistent with CLN2 disease, such as developmental delay or decline, seizures, vision loss, or an older sibling with confirmed CLN2 diagnosis.
• Currently receiving biweekly ICV ERT treatment with cerliponase alfa.
• Age ≥24 month and ≤84 months at screening
• In the phase of accelerated decline in CRT with the following baseline retinal criteria confirmed by the central reading center:
‣ CRT ≤210 μm and
⁃ CRT ≥140 μm in both eyes and
• Is willing and able to comply with the protocol and 5-year visit schedule.
∙ Written informed consent must be provided by the participants parent(s) or legally authorized representative(s)